QYUNS-B: POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 31, 2024
QYUNS-B: VOLUNTARY ANNOUNCEMENT FIRST SUBJECT ENROLLMENT FOR QX005N PHASE III CLINICAL TRIAL FOR THE TREATMENT OF PRURIGO NODULARIS
QYUNS-B: CLARIFICATION ANNOUNCEMENT SUPPLEMENTAL NOTICE AND REVISED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 31, 2024
QYUNS-B: REVISED FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 31, 2024
QYUNS-B: SUPPLEMENTAL NOTICE OF 2023 ANNUAL GENERAL MEETING
QYUNS-B: VOLUNTARY ANNOUNCEMENT QYUNS OBTAINED IND CLEARANCE FOR QX013N FOR TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN CHINA
QYUNS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024
QYUNS-B: FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 31, 2024
QYUNS-B: NOTICE OF 2023 ANNUAL GENERAL MEETING
QYUNS-B: (1) 2023 WORK REPORT OF THE BOARD (2) 2023 WORK REPORT OF THE BOARD OF SUPERVISORS (3) 2023 ANNUAL REPORT; (4) 2023 PROFIT DISTRIBUTION PLAN; (5) 2024 REMUNERATION SCHEME FOR DIRECTORS AND SUPERVISORS; (6) ENGAGEMENT OF THE AUDITOR FOR 2024; (7) PROPOSED G
QYUNS-B: 2023 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
QYUNS-B: 2023 ANNUAL REPORT
QYUNS-B: VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE
QYUNS-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
QYUNS-B: FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
QYUNS-B: ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS
QYUNS-B: List of Directors and their Roles and Functions
QYUNS-B: Terms of Reference of the Strategy and Development Committee
QYUNS-B: Terms of Reference of the Remuneration and Appraisal Committee
QYUNS-B: Terms of Reference of the Nomination Committee
No Data